Shire Plc won a U.S. court ruling blocking generic versions of its best-selling product, the Vyvanse treatment for attention deficit hyperactivity disorder (Shire LLC v. Amneal Pharms., LLC, 2014 BL 174718, D.N.J., 2:11-cv-03781-SRC-CLW, unpublished 6/23/14).
U.S. District Judge Stanley R. Chesler in New Jersey found that Shire’s patents on the drug are valid and would be infringed if five generic-drug companies introduced copies of the medicine, Shire said in a statement June 25.
Unless the generic companies win an appeal, they will be blocked from introducing a copy of the drug until the patents expire in 2023, Dublin-based ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.